重症肌无力新药卓倍可 中国获批

Core Viewpoint - UCB has received approval from China's National Medical Products Administration (NMPA) for the marketing authorization of Zilucoplan (brand name: Zhuobeike), a new treatment for adult patients with generalized myasthenia gravis who are positive for anti-acetylcholine receptor (AChR) antibodies [1] Group 1 - Zilucoplan is the first and only subcutaneously administered C5 complement inhibitor that can be self-administered, featuring a dual inhibition mechanism [1] - The drug effectively blocks complement-mediated damage at the neuromuscular junction, providing a new treatment option for patients [1] - Patients can complete the subcutaneous injection at home in just 5-8 seconds, enhancing convenience and accessibility [1] Group 2 - With this approval, UCB now offers both Zilucoplan and Rozanolixizumab in China, making it the only biopharmaceutical company globally to provide two targeted treatment options for generalized myasthenia gravis [1] - This development enriches disease management choices for patients with generalized myasthenia gravis, addressing different medical needs [1]